AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
CytoMed Therapeutics Limited Ordinary Shares
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG01BM32GN0
0.92▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.92
Day's Range
0.84 – 0.92
52-Week Range
0.68 – 3.10
Volume
4,284
Avg Volume
17.3K
Share Statistics
Shares Outstanding
Employees
42
Exchange
XNAS
Listed
2023-04-14
Share count as of December 31, 2025

CytoMed Therapeutics Limited Ordinary Shares (GDTC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about CytoMed Therapeutics Limited Ordinary Shares (GDTC)
What is CytoMed Therapeutics Limited Ordinary Shares's Market Cap?
CytoMed Therapeutics Limited Ordinary Shares's Market Cap is $10.9M, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Enterprise Value?
CytoMed Therapeutics Limited Ordinary Shares's Enterprise Value is $9.6M, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Price / Sales?
CytoMed Therapeutics Limited Ordinary Shares's Price / Sales is 43.1×, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's EV / Revenue?
CytoMed Therapeutics Limited Ordinary Shares's EV / Revenue is 37.9×, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Revenue (TTM)?
CytoMed Therapeutics Limited Ordinary Shares's Revenue (TTM) is $252.3K, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Net Income (TTM)?
CytoMed Therapeutics Limited Ordinary Shares's Net Income (TTM) is -$3.1M, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Diluted EPS (TTM)?
CytoMed Therapeutics Limited Ordinary Shares's Diluted EPS (TTM) is -0.26, based on as-reported figures from SEC (XBRL) filings.
What is CytoMed Therapeutics Limited Ordinary Shares's Net Debt?
CytoMed Therapeutics Limited Ordinary Shares's Net Debt is -$1.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GDTCAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of SGD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Profit or loss [abstract]
Revenue
Operating Income
Non-Operating Income (Expense)
Lab consumables and cord-blood banking expenses
Research expenses
Depreciation of property, plant and equipment
Amortization of intangible assets
Employee benefits expenses
Finance expenses
Other expenses
Income from Equity Method Investments
Loss before income tax
Income tax expense—
Loss for the year
Other comprehensive (loss)/income:
Foreign currency translation (loss)/gain
Total comprehensive loss for the year
Loss attributable to:
Net Income
Non-controlling interests